HighTower Advisors LLC Has $1.23 Million Holdings in TransMedics Group, Inc. $TMDX

HighTower Advisors LLC lifted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 137.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,257 shares of the company’s stock after purchasing an additional 10,575 shares during the quarter. HighTower Advisors LLC owned approximately 0.05% of TransMedics Group worth $1,228,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of TMDX. Braidwell LP acquired a new stake in shares of TransMedics Group during the 4th quarter worth approximately $57,493,000. Mackenzie Financial Corp lifted its position in shares of TransMedics Group by 73.0% during the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock worth $51,635,000 after buying an additional 349,403 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of TransMedics Group by 1,565.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company’s stock worth $16,820,000 after buying an additional 253,624 shares during the period. Avidity Partners Management LP lifted its position in shares of TransMedics Group by 597.1% during the 4th quarter. Avidity Partners Management LP now owns 192,400 shares of the company’s stock worth $11,996,000 after buying an additional 164,800 shares during the period. Finally, Frontier Capital Management Co. LLC bought a new position in shares of TransMedics Group during the 4th quarter worth approximately $9,415,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research report on Monday. Piper Sandler restated an “overweight” rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Morgan Stanley raised their target price on TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Oppenheimer raised their target price on TransMedics Group from $130.00 to $150.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 17th. Finally, Canaccord Genuity Group raised their target price on TransMedics Group from $129.00 to $142.00 and gave the stock a “buy” rating in a research report on Tuesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $123.00.

Insider Buying and Selling

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the business’s stock in a transaction on Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the transaction, the insider owned 13,955 shares of the company’s stock, valued at approximately $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Price Performance

TransMedics Group stock opened at $114.97 on Tuesday. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The firm has a market cap of $3.92 billion, a P/E ratio of 59.57 and a beta of 2.09. The business’s fifty day moving average is $121.11 and its two-hundred day moving average is $102.00. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.00.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.44. The company had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business’s revenue was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. Equities research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.